ad image

HIV

1 / 2
CytoDyn Takes Steps towards a Brighter Future
Therapeutic Candidate

CytoDyn Takes Steps towards a Brighter Future

Cyrus Arman, Ph.D.

CytoDyn

PAO-02-23-CL-04Feb 06, 2023
GSK
Collaboration

ViiV Healthcare and Halozyme Enter Global Collaboration for ENHANZE® Drug Delivery Technology to Enable Development of “Ultra Long-Acting” Medicines for HIV

GSK

PR-M06-21-032Jun 25, 2021
Johnson & Johnson
HIV Prevention

Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine with the Imbokodo Study

Johnson & Johnson

PR-M07-20-NI-026Jul 16, 2020
GSK
HIV

ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP

GSK

PR-M05-20-NI-034-1543May 22, 2020
National Institutes of Health (NIH)
HIV

NIH Launches New Collaboration to Develop Gene-based Cures for Sickle Cell Disease and HIV on Global Scale

National Institutes of Health (NIH)

PR-M10-19-NI-033Oct 24, 2019
The US Food & Drug Administration
HIV Prevention

FDA Approves Second Drug to Prevent HIV Infection as Part of Ongoing Efforts to End the HIV Epidemic

The US Food & Drug Administration

PR-M10-19-NI-008Oct 07, 2019
HIV Vaccine to be Tested in the U.S. and Europe
Vaccine

HIV Vaccine to be Tested in the U.S. and Europe

Pharma's Almanac

PAO-M08-19-NI-008Aug 01, 2019
Upcoming HIV Study to Focus on Chronic Conditions Affecting People with AIDS
HIV/AIDS

Upcoming HIV Study to Focus on Chronic Conditions Affecting People with AIDS

Pharma's Almanac

PAO-M06-19-NI-013Jun 20, 2019
Gilead Sciences
HIV

Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic

Gilead Sciences

PR-M05-19-NI-038May 14, 2019
Abbott
Prequalification Approval

Abbott Receives WHO Prequalification Approval for Breakthrough HIV Point-of-Care Test

Abbott

PR-M05-19-NI-017May 06, 2019
Texas Biomed
Funding

Mymetics receives HIV Vaccine Funding from the NIH

Texas Biomed

PR-M05-19-NI-004May 01, 2019
United BioPharma
Clinical Data

United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine

United BioPharma

PR-M04-19-NI-066Apr 22, 2019
Descovy Shown to be As Effective and Safer than Truvada as a Preventive HIV Treatment
HIV Prevention

Descovy Shown to be As Effective and Safer than Truvada as a Preventive HIV Treatment

Pharma's Almanac

PAO-M04-19-NI-011Apr 10, 2019
Johnson & Johnson
HIV

Long-Acting Injectable HIV Treatment Regimen of Rilpivirine and Cabotegravir Demonstrated Comparable Safety and Efficacy to Daily Oral HIV Therapy

Johnson & Johnson

PR-M03-19-NI-033Mar 12, 2019
GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy
FDA Approval

GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy

Emilie Branch

Pharma's Almanac

PAO-M10-18-NI-029Oct 29, 2018
Gilead Sciences
HIV Diagnoses

Gilead Announces New Data on the Impact of Truvada® for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States

Gilead Sciences

PR-M07-18-NI-087Jul 26, 2018
Merck & Co.
HIV Therapy

Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine

Merck & Co.

PR-M07-18-NI-083Jul 25, 2018
Mylan
Drug Development

Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.

Mylan

PR-M03-18-NI-023Mar 07, 2018
Gilead Sciences

Gilead Announces Data from New Preclinical Study Evaluating a Combination of an Investigational TLR7 Agonist and an Investigational HIV Envelope

Gilead Sciences

PR-M03-18-NI-021Mar 06, 2018
Merck & Co.
Clinical Data

Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018

Merck & Co.

PR-M03-18-NI-015Mar 05, 2018
1 / 2